An advanced well-differentiated pancreatic neuroendocrine carcinoma (NET-G3) associated with von hippel-lindau disease

Masami Miki, Ken Kawabe, Hisato Igarashi, Tatsuro Abe, Yoshihiro Ohishi, Risa Hashimoto, Takashi Karashima, Ichiro Yamasaki, Keiji Inoue, Tetsuhide Ito, Yoshihiro Ogawa

Research output: Contribution to journalArticle

Abstract

A 45-year old woman who underwent several surgeries for tumors associated with von Hippel-Lindau disease (VHL) was referred to our hospital due to a pancreatic tumor and liver tumors. She was diagnosed with pancreatic neuroendocrine tumor (NET) with a Ki67 index of 40% based on the examination of a biopsy specimen of the liver tumors. She was treated with everolimus for 6 months and sunitinib for 6 weeks as first-and second-line therapies. She survived for 13 months. At autopsy the diagnosis of pancreatic neuroendocrine tumor (NET)-G3 was confirmed. We herein report an aggressive clinical course of VHL-related NET G3. The further accumulation of cases is required to reach a consensus on treatment for this disease.

Original languageEnglish
Pages (from-to)2007-2011
Number of pages5
JournalInternal Medicine
Volume57
Issue number14
DOIs
Publication statusPublished - Jan 1 2018

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Fingerprint Dive into the research topics of 'An advanced well-differentiated pancreatic neuroendocrine carcinoma (NET-G3) associated with von hippel-lindau disease'. Together they form a unique fingerprint.

  • Cite this

    Miki, M., Kawabe, K., Igarashi, H., Abe, T., Ohishi, Y., Hashimoto, R., Karashima, T., Yamasaki, I., Inoue, K., Ito, T., & Ogawa, Y. (2018). An advanced well-differentiated pancreatic neuroendocrine carcinoma (NET-G3) associated with von hippel-lindau disease. Internal Medicine, 57(14), 2007-2011. https://doi.org/10.2169/internalmedicine.0416-17